Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
PA8 Stock Overview
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide.
Paion Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.94 |
52 Week High | €2.01 |
52 Week Low | €0.87 |
Beta | 0.95 |
1 Month Change | -18.35% |
3 Month Change | -29.19% |
1 Year Change | -45.79% |
3 Year Change | -56.33% |
5 Year Change | -63.18% |
Change since IPO | -89.46% |
Recent News & Updates
Shareholder Returns
PA8 | DE Biotechs | DE Market | |
---|---|---|---|
7D | -7.9% | 4.3% | -0.1% |
1Y | -45.8% | -31.4% | -12.9% |
Return vs Industry: PA8 underperformed the German Biotechs industry which returned -31.4% over the past year.
Return vs Market: PA8 underperformed the German Market which returned -12.9% over the past year.
Price Volatility
PA8 volatility | |
---|---|
PA8 Average Weekly Movement | 8.4% |
Biotechs Industry Average Movement | 8.2% |
Market Average Movement | 6.3% |
10% most volatile stocks in DE Market | 10.7% |
10% least volatile stocks in DE Market | 3.5% |
Stable Share Price: PA8 is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: PA8's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 56 | Jim Phillips | https://www.paion.com |
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company’s lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.
Paion Fundamentals Summary
PA8 fundamental statistics | |
---|---|
Market Cap | €66.99m |
Earnings (TTM) | -€21.79m |
Revenue (TTM) | €7.13m |
9.4x
P/S Ratio-3.1x
P/E RatioIs PA8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PA8 income statement (TTM) | |
---|---|
Revenue | €7.13m |
Cost of Revenue | €3.08m |
Gross Profit | €4.05m |
Other Expenses | €25.84m |
Earnings | -€21.79m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 24, 2022
Earnings per share (EPS) | -0.31 |
Gross Margin | 56.83% |
Net Profit Margin | -305.62% |
Debt/Equity Ratio | 0% |
How did PA8 perform over the long term?
See historical performance and comparisonValuation
Is Paion undervalued compared to its fair value and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PA8 (€0.94) is trading below our estimate of fair value (€53.15)
Significantly Below Fair Value: PA8 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PA8 is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: PA8 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PA8's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PA8 is overvalued based on its PB Ratio (9.6x) compared to the DE Biotechs industry average (1.5x).
Future Growth
How is Paion forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score
5/6Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
67.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PA8 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.05%).
Earnings vs Market: PA8 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PA8's is expected to become profitable in the next 3 years.
Revenue vs Market: PA8's revenue (49.1% per year) is forecast to grow faster than the German market (4.7% per year).
High Growth Revenue: PA8's revenue (49.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PA8's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Paion performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
15.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PA8 is currently unprofitable.
Growing Profit Margin: PA8 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PA8 is unprofitable, but has reduced losses over the past 5 years at a rate of 15% per year.
Accelerating Growth: Unable to compare PA8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PA8 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: PA8 has a negative Return on Equity (-311.26%), as it is currently unprofitable.
Financial Health
How is Paion's financial position?
Financial Health Score
3/6Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: PA8's short term assets (€16.2M) exceed its short term liabilities (€11.0M).
Long Term Liabilities: PA8's short term assets (€16.2M) do not cover its long term liabilities (€18.8M).
Debt to Equity History and Analysis
Debt Level: PA8 is debt free.
Reducing Debt: PA8 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PA8 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: PA8 has less than a year of cash runway if free cash flow continues to grow at historical rates of 8.6% each year.
Dividend
What is Paion current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PA8's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PA8's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PA8's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PA8's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PA8 has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
4.9yrs
Average board tenure
CEO
Jim Phillips (59 yo)
2.58yrs
Tenure
€427,599
Compensation
Dr. James Neil Phillips, also known as Jim, MB, ChB, M.D., MBA, serves as Chairman of Management Board and Chief Executive Officer of Paion AG since October 16, 2019. Dr. Phillips serves as the Chief Execu...
CEO Compensation Analysis
Compensation vs Market: Jim's total compensation ($USD451.10K) is about average for companies of similar size in the German market ($USD404.30K).
Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.
Board Members
Experienced Board: PA8's board of directors are considered experienced (4.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Paion AG's employee growth, exchange listings and data sources
Key Information
- Name: Paion AG
- Ticker: PA8
- Exchange: XTRA
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €66.985m
- Shares outstanding: 71.34m
- Website: https://www.paion.com
Number of Employees
Location
- Paion AG
- Heussstraße 25
- Aachen
- North Rhine-Westphalia
- 52078
- Germany
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/21 00:00 |
End of Day Share Price | 2022/05/20 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.